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AG129e virus (DENV1–4) are causative agents of dengue fever and dengue hemorrhagic
fever/dengue shock syndrome (DHF/DSS). Previous DENV infection is a risk factor for DHF/DSS during
subsequent infection by a different serotype. Nonetheless, most primary and secondary DENV infections are
asymptomatic. To investigate the possible mechanisms of immune protection in vivo, 129/Pas mice lacking
IFN-α/β and -γ receptors (AG129) were used to model secondary infection using both DENV1–DENV2 and
DENV2–DENV4 sequences. At intervals between sequential infections of 4 to 52 weeks, protection against
secondary heterologous DENV infection was observed. Passive transfer of DENV-immune serum was
protective against replication of heterologous challenge virus in all tissues tested, whereas adoptive transfer
of DENV-immune cells signiﬁcantly protected mice from replication of the challenge virus only when a lower
inoculumwas administered. These ﬁndings are relevant for understanding both natural and vaccine-induced
immunity to DENV.
© 2008 Elsevier Inc. All rights reserved.IntroductionThe four serotypes of dengue virus (DENV1–4), in the genus Fla-
vivirus, family Flaviviridae, are the causative agents of the mosquito-
borne illness dengue fever (DF), which affects over 50 million people
annually. In some cases, DF progresses to dengue hemorrhagic fever/
dengue shock syndrome (DHF/DSS), which is a severe, life-threatening
disease characterized by increased vascular permeability and respon-
sible for 250,000–500,000 hospitalizations each year in tropical and
sub-tropical regions worldwide (Gubler, 1998). Although a number of
dengue vaccine candidates are in various stages of clinical trials, no
speciﬁc therapies or vaccines are currently available (Hombach, 2007;
Whitehead et al., 2007). A successful tetravalent dengue vaccine must
confer robust protection against all four serotypes of DENV, as
previous infection by one serotype is a recognized risk factor for
DHF/DSS following a heterologous (cross-serotype-reactive) DENV
infection (Halstead, 1981). Nonetheless, most primary and secondary
DENV infections are asymptomatic (Balmaseda et al., 2006; Burke et
al., 1988; Endy et al., 2002), and the mechanistic basis of protection
versus enhancement in sequential DENV infections is not well-ases, School of Public Health,
erkeley, CA, 94720-7354, USA.
l rights reserved.deﬁned. Epidemiologic studies in humans yield invaluable informa-
tion; however, animal models of DENV infection allow characteriza-
tion of protective as well as pathologic immune responses during a
secondary DENV infection in vivo.
Studies of heterologous DENV infections have been conducted in
non-human primates and to a limited extent in mice. In monkeys,
sequential heterologous DENV infections resulted in either protection
(Kochel et al., 2005), partial protection (Koraka et al., 2007; Scherer et
al., 1972) or enhancement (Marchette et al., 1973). Enhanced infection
after transfer of either pooled human cord blood from DENV-immune
mothers (Halstead, 1979) or a chimeric human-chimpanzee anti-DENV
neutralizing monoclonal antibody (mAb) (Goncalvez et al., 2007)
resulted in increased viremia in rhesus monkeys that is postulated to
represent antibody-dependent enhancement (ADE). In mice, protection
from death using a secondary, homologous (serotype-speciﬁc) DENV
infection has been demonstrated (Johnson and Roehrig, 1999; Price and
Thind, 1972); while reports of heterologous sequential DENV infections
in mice noted an increase in thrombocytopenia (Sarkar et al., 1976) or
documented heterologous immune responses (Beaumier et al., 2008).
To the best of our knowledge, no published study in mice has
documented the occurrence of either protection or enhancement of
DENV titers in sequential, heterologous infections.
Wildtype mice are susceptible to DENV infection only after high
doses and do not manifest robust viral replication (Chen et al., 2004;
Huang et al., 2000; Paes et al., 2005; Shresta et al., 2004a). Thus,
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to DENV in vivo (An et al., 1999, 2004; Bente et al., 2005; Blaney et al.,
2002; Johnson and Roehrig,1999; Lin et al., 1998; Shresta et al., 2004b;
Wu et al., 1995). In this study, mice of the 129 strain lacking receptors
for interferon (IFN)-α/β and IFN-γ (AG129) were used to model
sequential DENV infections. AG129 mice have a number of relevant
attributes; for instance, they support robust replication of clinical
isolates of all four DENV serotypes (Kyle et al., 2007; Shresta et al.,
2004b";; S. Balsitis and E. Harris, unpublished data), display cellular
tropism similar to that seen in humans (Durbin et al., 2008; Kyle et al.,
2007; Neves-Souza et al., 2005), exhibit thrombocytopenia that is
inversely related to viral load (S. Balsitis and E. Harris, unpublished
data), develop high levels of soluble non-structural 1 (NS1) protein
during DENV infection comparable to levels seen in humans (Schul et
al., 2007; S. Balsitis and E. Harris, unpublished data), and experience
increased vascular permeability upon infection with certain DENV
strains (Shresta et al., 2006). In addition, AG129 mice are currently
used to test anti-DENV compounds (Schul et al., 2007) and vaccines
(Calvert et al., 2006; Huang et al., 2003; Johnson and Roehrig, 1999).
An important advantage of the AG129 mouse strain is that it allows
investigation of the adaptive immune response to DENV infection,
since the adaptive immune system appears to be intact (van den Broek
et al., 1995), with the caveat that IFN-mediated interactions between
the innate and adaptive arms of immunity are lacking. Speciﬁcally,
AG129micewere found to have normal numbers of major lymphocyte
subsets and normal levels of constitutive MHC expression.
To dissect the role of humoral versus cellular immune responses in
secondary DENV infection, we conducted two types of experiments in
AG129mice: (1) sequential infectionwith two distinct serotypes or (2)
passive transfer of DENV-immune serum or adoptive transfer of
DENV-immune cells to naive recipients, followed by challenge with a
heterologous serotype. Serotype-cross-protective immunity, rather
than enhancement, was observed up to one year after infection withFig. 1. Previous DENV1 infection protects against DENV2 challenge. Mice were infected with
Mice were challenged at (A) 4, (B) 15, (C) 33, or (D) 52 weeks post-DENV1 infectionwith 105 P
tissue from the spleen, lymph nodes (LN), serum, and bone marrow cells (BM). Results from 2
below the limit of detection).two different serotype sequences. Passive and adoptive transfer
experiments suggested that protection was primarily mediated by
heterologous antibodies, but also revealed a potential contribution by
serotype-cross-reactive immune cells.
Results
Primary DENV infection in mice confers protection against a
heterologous DENV serotype in sequential infections
We and others have previously demonstrated that AG129 mice are
highly susceptible to multiple DENV serotypes and strains (Johnson
and Roehrig, 1999; Schul et al., 2007; Shresta et al., 2004b) and that
the cellular tropism of DENV in AG129 mice is similar to that seen in
humans (Kyle et al., 2007). Using the AG129 model system, we tested
two different combinations of DENV sequential infections. Mice were
ﬁrst infected with DENV1 and then challenged with 105 PFU of DENV2
4, 15, 33, or 52 weeks later. Each DENV2 challenge experiment
included an equal number of naive, age-matched controls. Spleen,
lymph nodes, blood and bone marrow cells were collected from all
mice at day 3 p.i., which is the day of peak replication (Kyle et al.,
2007), and viral load in each tissue was determined by plaque assay.
Reduced or absent replication of the DENV2 challenge serotype was
observed in DENV1-immunemice as compared to naive controls at 4-,
15- and 33-week intervals between infections (Fig. 1). Of note,
protection against DENV2 replication in the bone marrow at the
earliest timepoint (4 weeks post-DENV1 infection) is incomplete. This
may correlate with lower initial levels of cross-serotype protective
antibodies, as discussed below. At the longest time interval tested
(52 weeks), heterologous protection against DENV2 had begun to
wane in DENV1-immunemice, although DENV2 titers were still below
the level of replication observed in naive mice. Statistics were not
performed based on the low numbers of mice in each group, but theDENV1 98J or Mochizuki (□), and age-matched naive mice were used as controls (▪).
FU DENV2 PL046. At day three post-DENV2 infection, plaque assays were performed on
to 3 mice per group are shown, and each bar represents an individual mouse (⁎; values
Fig. 2. Prior DENV2 infection protects against DENV4 challenge. Micewere infectedwith
DENV2 PL046 (□), and age-matched naive mice were used as controls (▪). Mice were
challenged at (A) 4, (B) 15, or (C) 52weeks post-DENV2 infectionwith 104 PFU of DENV4
664. At day 4 or 5 post-DENV4 infection, plaque assays were performed on tissue from
the lymph nodes (LN) and bone marrow cells (BM). Since titers of DENV4 in serum and
spleen of naive mice are not sufﬁciently robust to detect a difference between groups,
theywere not included in the assessment. Results from 2 to 3mice per group are shown,
and each bar represents an individual mouse (⁎; values below the limit of detection).
Fig. 3. Cross-reactive neutralizing antibodies are present up to 20 weeks after primary
DENV1 and DENV2 infection. Mice were infected with either (A) 102 PFU of DENV1
strain Mochizuki or (B) 105 PFU of DENV2 strain PL046. Results are shown for DENV1-
immune serum (A) using DENV1 (♦) or DENV2 (◊) in the PRNT assay; and results for
DENV2-immune serum (B) are shown using DENV2 (●) or DENV4 (○). The limit of
detection for PRNT values is b1:10. Normal AG129 serum had a neutralizing value of
b1:10 against all three DENV strains.
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DENV1-immunemice up to 33weeks post-infection (p.i.) is suggestive
of extended cross-serotype protection in sequential infections.
To conﬁrm that protection in this heterologous DENV infection
model was not restricted to one sequence of serotypes, we also
infected AG129 mice with DENV2, followed by a secondary hetero-
logous infection with 104 PFU of DENV4. Lymph nodes and bone
marrow cells were collected from all mice at day 4–5 p.i., which are
the days of peak replication (data not shown). Secondary DENV4
infections were performed after intervals of 4, 15 and 52 weeks, and
DENV2-immune mice were protected against heterologous DENV4 at
each time interval up to and including 52weeks after infection (Fig. 2).
Cross-neutralizing DENV-speciﬁc antibodies are present for at least
20 weeks post-infection
In humans, long-term, serotype-speciﬁc neutralizing antibodies
have been found 40 years post-primary infection (Innis, 1997), and the
presence of both serotype-speciﬁc and serotype-cross-reactive anti-
bodies has been documented (Guzman et al., 2007; Kochel et al.,2002). We tested for the presence of both serotype-speciﬁc and
serotype-cross-reactive neutralizing antibodies in mice that had
received a primary DENV1 or DENV2 infection. AG129 mice were
infected with either DENV1 or DENV2, and 50% plaque reduction
neutralization tests (PRNT50) were performed (Fig. 3). The limit of
detection for PRNT50 titers was b1:10, and naive AG129 sera had a
neutralizing titer of b1:10 against all DENV strains tested.
A serotype-speciﬁc antibody response of AG129 mice to DENV1
infection was detected by 2 weeks p.i., and high levels of DENV1-
neutralizing antibodies were present through at least 20 weeks p.i.
(Fig. 3A). Heterologous neutralizing antibodies against DENV2 were
just at the level of detection at 4 weeks p.i., which may explain in part
the lower level of cross-protection seen at this early timepoint (Fig.1A),
as compared to later timepoints when the titers were higher (Fig. 3A).
Cross-serotype protective antibodies began to decline after 16weeks p.
i., but were still present until at least 20 weeks p.i. Similarly, DENV2
infection induced robust neutralizing titers against DENV2 as detected
by PRNT50 beginning 2 weeks p.i. Serotype-cross-reactive neutralizing
antibodies against DENV4 serotype were also present, beginning
2weeks p.i. and lasting until at least 16weeks p.i. (Fig. 3B). In a separate
experiment, neutralizing antibodies were measured at 61 weeks after
infection with either DENV1 (n=2) or DENV2 (n=2). In DENV1-
immune mice, the PRNT50 titers against DENV1 were 1:1792 and
1:870, and the PRNT50 titers against the heterologous DENV2 were
1:117 and 1:100. In DENV2-immune mice, the PRNT50 titers against
DENV2 were 1:586 and 1:337, whereas the PRNT50 titers against
DENV4 were 1:29 and 1:21. Thus, DENV-immune mouse serum
contains both homologous and heterologous neutralizing antibodies
over an extended time period after primary infection.
Passive transfer of DENV-immune serum confers protection against
homologous and heterologous DENV challenge
To examine the capacity of antibodies to protect against DENV
challenge in AG129 mice, we ﬁrst passively transferred mAbs or
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transfer experiments, antiserum was delivered via an intraperitoneal
(ip) route 24 h prior to infectionwith 105 PFU DENV2 strain PL046. For
experiments involving transfer of polyclonal antiserum, pre-challenge
sera were tested by PRNT in a subset of mice. Effective neutralizing
titers in recipient mice demonstrated a 1:10 dilution of transferred
sera (data not shown). Non-parametric statistics (the Wilcoxon Rank
Sum test) were used for analysis of both passive and adoptive transfer
studies, in order to avoid statistical assumptions about the data
analyzed. With this test, p-values are not derived from the magnitude
of the difference between groups, but rather from the extent of
overlap in the values for the two datasets being compared. In these
experiments, we have deﬁned protection against viral challenge as a
signiﬁcant reduction in viral titers in the tissues tested.
A neutralizing mAb directed against the DENV2 envelope (E)
protein (3H5) resulted in reduced titers of the DENV2 challenge
(Fig. 4A), with a 3-log reduction of viral titers in the spleen
(p=0.0495) and a 1-log reduction in the lymph nodes (p=0.0495) at
day 3 p.i. Passive transfer of 300 μL of polyclonal anti-DENV2 sera
(PRNT50 titer against DENV2=1:1225) completely protected mice
from DENV2 replication in spleen (p=0.0369) and serum and
substantially reduced levels of viral replication in the lymph nodes
(Fig. 4B). Next, to test the capacity of DENV1-immune serum to
provide heterologous protection against a DENV2 challenge, we
passively transferred 400 μL of DENV1-immune sera (PRNT50 titer
against DENV1=1:663 and against DENV2=1:276) and subsequentlyFig. 4. Passive transfer of both monoclonal and polyclonal antibodies protects against
homologous as well as heterologous DENV2 challenge. AG129 mice received passive
transfer of DENV-immune serum via an intraperitoneal injection 24 h prior to
homologous or heterologous challenge. All mice were challenged with 105 PFU of
DENV2 strain PL046. Three days post-infection, plaque assays were performed on tissue
from the blood, spleen and lymph nodes. (A) Mice received 250 μg of the neutralizing
anti-DENV2 monoclonal antibody 3H5 (□) or 250 μg of the anti-DENV1 monoclonal
antibody 15F3 as an isotype control (▪); n=3/group under each condition. (B) Mice
received 300 μL of DENV2-immune serum (□) or normal mouse serum (▪); n=3/group
under each condition. (C) Mice received 400 μL of DENV1-immune serum (□) (n=4),
and controls received either 400 μL of normal mouse serum (n=2) or no serum (n=2)
(▪). (⁎; value below the limit of detection; §, p=value of b0.05 by Wilcoxon Rank Sum
test).
Fig. 5. Adoptive transfer of DENV-immune cells confers partial homologous and
heterologous protection. DENV-immune spleen cells were adoptively transferred into
AG129 mice via intravenous injection 24 h prior to homologous or heterologous
challenge. Three days post-infection, plaque assays were performed on tissue from the
blood, spleen and lymph nodes. (A) Interferon-γ responses from donor cells used for
adoptive transfer experiments in response to stimulation with control antigen (▪) or
DENV2 antigen (□). (B) Each mouse received 3×107 naive spleen cells (▪), DENV1-
immune spleen cells ( ) or DENV2-immune spleen cells (□), followed by challenge
with 105 PFU of DENV2 PL046 (n=3 mice/group). (C) Each mouse received 3×107 naive
spleen cells (▪), DENV1-immune spleen cells ( ) or DENV2-immune spleen cells (□),
followed by challenge with 3×104 PFU of DENV2 PL046 (n=6–7 mice/group). (⁎; value
below the limit of detection; §, p=value of b0.05 by Wilcoxon Rank Sum test as
compared to control mice receiving naive cells).challenged mice sc with DENV2. This resulted in a 1–2-log reduction
in viral titers in the spleen (p=0.0209), lymph nodes (p=0.0433), and
serum (p=0.0455) of infected mice (Fig. 4C). As was observed in the
sequential infection studies, reduction of viral titers in the lymph
nodes was less complete than that observed in spleen tissue.
Adoptive transfer of DENV-immune cells confers partial protection
against both homologous and heterologous DENV infection
Previously, the presence of serotype-speciﬁc and serotype-cross-
reactive DENV-speciﬁc T cells in mice after infection with all four
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detectable one year p.i. (Rothman et al., 1996, 1989). Even though
neutralizing antibodies appear capable of mediating homologous and
heterologous protection in vivo, this does not discount a complemen-
tary and/or synergistic means of protection by the cellular immune
response. Therefore, we tested whether adoptive transfer of DENV-
immune spleen cells could mediate a reduction in viral titers after
homologous and/or heterologous challenge.
Immune spleen cells were transferred into naive mice via iv tail-
vein injection performed 24 h before sc infection with DENV2 PL046.
The ability to successfully transfer total spleen cells after iv injection
was conﬁrmed in a subset of mice by detection of CFSE-stained cells in
recipientmice 24–36 h following transfer of 1.5×107 cells/mouse (data
not shown). Moreover, donor spleen cells from DENV2-immune mice
were capable of responding to stimulation with DENV2 cellular
antigen by secretion of IFN-γ as detected by ELISA (Fig. 5A). In
contrast, neither naive spleen cells nor DENV1-immune cells
produced IFN-γ after stimulation with DENV2 cellular antigen. All
donor spleen cells produced IFN-γ in response to concanavalin A,
conﬁrming their capacity to produce IFN-γ upon stimulation (data not
shown).
After transfer of 3×107 cells/mouse, mice were infected 24 h
later with 105 PFU DENV2, and spleen, lymph nodes and blood were
collected on day 3 p.i. for plaque assay analysis. A reduction of viral
titers was observed in spleen tissue in mice that received DENV2-
immune spleen cells (p=0.0495) (Fig. 5B). No reduction was
observed in the lymph nodes and serum, nor was protection
observed in any tissue after iv transfer of either naive or DENV1-
immune cells under these conditions. We performed additional
adoptive transfer studies involving a lower challenge dose (3×104
PFU of DENV2) to determine if a lower viral inoculum could reveal a
protective role for immune cells in heterologous infection. A
statistically signiﬁcant reduction of viral titers was observed in the
spleen after both homologous (p=0.0127) and heterologous
(p=0.0027) challenge, but this reduction was not observed in the
lymph nodes or serum even following challenge with the lower viral
dose (Fig. 5C).
Discussion
For up to one year after primary infection, protection against
heterologous DENV challenge was observed in AG129 mice using two
separate viral sequences (DENV1–DENV2 and DENV2–DENV4), as
evidenced by a reduction in viral titers at early timepoints p.i. To test
which arm of the immune response (humoral versus cellular) was
responsible, either DENV-immune serum or DENV-immune spleen
cells were transferred into naive recipients, followed by challenge
with a heterologous DENV serotype. Passive transfer of antibodies was
found to signiﬁcantly decrease levels of viral replication after both
homologous and heterologous challenge. Consistent with this, high
titers of homologous neutralizing antibodies and lower, but detect-
able, levels of cross-serotype-reactive neutralizing antibodies were
found up to over one year after primary infection. In comparison,
adoptive transfer of DENV-immune cells followed by DENV2 challenge
conferred signiﬁcant homologous and heterologous protection only at
a lower challenge dose. These results imply that heterologous
neutralizing antibodies alone could be responsible for the reduction
of viral titers observed in the heterologous sequential infectionmodel,
but that DENV-speciﬁc immune cells may also provide an important
contribution.
Previous evidence from studies in mice had shown that passive
transfer of either monoclonal or polyclonal antibodies can be
protective against homologous DENV challenge (Henchal et al.,
1988; Kaufman et al., 1989, 1987). The ﬁrst study using AG129 mice
with DENV found that passive transfer of either homologous
neutralizing monoclonal or polyclonal antibodies was poorlyprotective against neurovirulent death due to DENV2 challenge
with a mouse-passaged DENV2 (Johnson and Roehrig, 1999).
However, we observed an antibody-mediated reduction of viral
titers of a homologous DENV2 clinical isolate in peripheral tissues
following passive transfer of both monoclonal and polyclonal anti-
DENV2 antibodies. Of particular interest, we also observed hetero-
logous protection provided by anti-DENV1 sera, followed by DENV2
challenge. One recent study reported adoptive transfer of DENV-
immune cells followed by heterologous challenge, but as DENV
replicates poorly in immunocompetent BALB/c mice, it was not
possible to measure reduction or enhancement of viral replication in
this study (Beaumier et al., 2008). A study involving adoptive
transfer of a CD8+ T cell clone speciﬁc for DENV2 in HepG2-grafted
scid-mice reported equivocal results, as both protective (prolonged
survival) and pathogenic (shortened average survival time) effects
were observed (An et al., 2004). Of note, the adoptive transfer
studies performed in the current study involving DENV-immune
cells did not differentiate between T cells and B cells. Thus, the
possibility exists that adoptively transferred DENV-immune B cells
could have produced DENV-speciﬁc antibodies in response to
heterologous DENV challenge, and these antibodies might be able
to account for the protection observed in spleen tissue during the
adoptive transfer studies.
Although AG129 mice have proven to be a tractable system in
which to evaluate the mechanism of protection against DENV
replication in vivo, the immunocompromised nature of this strain
remains a limitation in translating these results directly to humans.
Nonetheless, an advantage of this model is that the early cellular
tropism of DENV in AG129 mice does remain restricted to the cell
types infected in humans (Kyle et al., 2007), unlike the widespread
changes in tropism observed after infection of IFN-receptor-deﬁcient
mice with other viruses (Fiette et al., 1995; Garcia-Sastre et al., 1998;
Mrkic et al., 1998; Ryman et al., 2000; Samuel and Diamond, 2005;
Steinhoff et al., 1995). AG129 mice have been shown to have a
normal repertoire of T cells (van den Broek et al., 1995), and
immune spleen cells used for adoptive transfer in this study were
found to respond to stimulation by DENV2 antigen as measured by
IFN-γ secretion, conﬁrming that antigen-speciﬁc recognition by
immune cells can develop in AG129 mice, even in the absence of
IFN receptors.
Studies of the long-term immune response in humans have
provided some interesting parallels for the data we report here.
Sabin (1950) reported that complete cross-protective immunity from
heterologous challenge was present in human volunteers for 1–
2 months after a primary DENV infection, with partial immunity
present up to 9 months resulting in milder disease of shorter duration
upon reinfection, and that complete serotype-speciﬁc immunity
against symptomatic dengue was present up to 18 months post-
infection (Sabin, 1950). Long-term, serotype-speciﬁc neutralizing
antibodies have been reported to be present 40 years after a single
dengue epidemic (Innis, 1997), and Cuban investigators have recorded
the long-term presence of both DENV-speciﬁc T cells and antibodies
up to 20 years after natural infection (Guzman et al., 2007; Sierra et al.,
2002).
Further studies of the heterologous neutralizing ability of anti-
DENV antibodies raised in AG129 mice will include investigation of
strain and serotype differences in neutralizing capacity, as well as
identiﬁcation of the DENV epitopes that correspond to this neutraliz-
ing ability. In parallel studies, we have also found that ADE can be
experimentally induced in the AG129 mouse under different condi-
tions and are currently further characterizing this phenomenon (S.
Balsitis, J.L. Kyle, P.R Beatty, E. Harris, unpublished data). The results of
this and future studies may thus contribute to a better understanding
of the factors that differentiate protection versus enhancement during
DENV infection, as well as an improved ability to evaluate candidate
dengue vaccines.
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Viruses and cell lines
DENV was propagated in C6/36 Aedes albopictus cells (American
Type Culture Collection [ATCC]) as described previously (Shresta et al.,
2004a). DENV1 Mochizuki (mouse-passaged; passage number
unknown) was obtained from R. Tesh (University of Texas Medical
Branch at Galveston, Texas); DENV1 98J (C6/36-passaged; used at
passage 7) is a clinical isolate from Guyana (Holden et al., 2006);
DENV2 PL046 (C6/36-passaged; passage number unknown) is a
Taiwanese clinical isolate (received from H.-Y. Lei, National Cheng
Kung University, Taiwan); and DENV4 664 (C6/36-passaged; used at
passage 4) is a Thai clinical isolate and a gift of S. Kliks (Pediatric
Dengue Vaccine Initiative, Berkeley, CA). Virus titers were obtained by
plaque assay on baby hamster kidney (BHK-21 clone 15; BHK) cells
(Shresta et al., 2004a). Before injection into mice, virus was diluted in
phosphate-buffered saline (PBS). Viral load in mice was determined in
tissue samples obtained from blood, lymph nodes, spleen and bone
marrow by plaque assay. Tissue samples were processed and
quantitated as described previously (Shresta et al., 2004a). Bone
marrow cells were collected from both femur and tibia bones directly
into PBS, and red blood cells in bone marrow were lysed using red cell
lysis buffer (eBioscience).
Infection of AG129 mice
AG129 mice (van den Broek et al., 1995) were originally obtained
from M. Aguet (Swiss Institute for Experimental Cancer Research,
Epalinges, Switzerland) and were bred in the University of California
(UC) Berkeley Northwest Animal Facility. All experimental procedures
were pre-approved and were performed according to the guidelines
of the UC Berkeley Animal Care and Use Committee. Experiments
were initiated with mice 5–8 weeks of age. Subcutaneous (sc)
injection was performed under the ventral skin of the hindlimbs, in a
total volume of 200 μL divided equally between both right and left
limbs, and intravenous injection was performed the tail vein in a total
volume of 200 μL. Sequential DENV1–DENV2 infections were
performed using either 102 or 104 PFU of DENV1 Mochizuki or 105
PFU of DENV1 98J as a primary infection, and 105 or 107 PFU of
DENV2 PL046 as a secondary infection. Sequential DENV2–DENV4
infections consisted of 105 PFU of DENV2 PL046 followed by 104 PFU
of DENV4 664.
Plaque reduction neutralization test (PRNT)
AG129 mice were infected with either 102 plaque forming units
(PFU) of DENV1 strain Mochizuki or 105 PFU of DENV2 strain PL046,
and monthly bleeds were staggered across two groups of mice, such
that serum was collected from 3 to 4 mice in the total cohort every
two weeks. Serum was collected from mice by retro-orbital bleed.
PRNT assays were performed in triplicate based on the original
protocol described by Russell et al (Russell et al., 1967). Brieﬂy,
complement was inactivated by incubating serum in a 56 °C water
bath for 30 min, then 5 serial 3-fold or 4-fold dilutions of serum
were prepared, starting at 1:10, in α-MEM (Invitrogen) with 5% fetal
bovine serum (FBS; Hyclone), 10 mM HEPES (Invitrogen), and 100 U
penicillin/100 μg streptomycin (P/S; Invitrogen). Working stocks of
virus were prepared that yielded 20–60 plaques/well in a 12-well
tissue culture plate. Viruses used for PRNT tests were DENV1 98J;
DENV2 PL046; and DENV4 664. Thirty μL of each serum dilution was
combined with 30 μL of virus and incubated for 90 min at 37 °C
with 5% CO2. After incubation, 50 μL of the virus-serum mixture was
transferred to 80% conﬂuent BHK cells and processed as in a
standard plaque assay. Percent neutralization for each well was
calculated as [1− (number of plaques in test wells /number ofplaques in control wells containing only virus)]⁎100. Fifty percent
neutralization titer (PRNT50) values were calculated for each sample
by ﬁtting a variable sigmoidal response curve in GraphPad Prism
5.00 (GraphPad Software), using ﬁxed constraints at the top and
bottom of b100% and N0%, respectively. Normal mouse serum
collected from naive AG129 mice (negative control) and the
neutralizing anti-ﬂavivirus antibody 4G2 (ATCC; positive control)
were included in each assay, as well as a back-titration prepared as a
1:10 dilution of each virus working stock. Serum dilution values are
expressed as the reciprocal of the original serum dilution, but not
including the 1:2 dilution factor introduced during the neutraliza-
tion step.
Preparation of antibodies and spleen cells for passive or adoptive transfer
MAbs 15F3 and 3H5 (ATCC) were puriﬁed by Protein G afﬁnity
chromatography (Pierce). Polyclonal anti-DENV serum used for
passive transfer and DEN-immune spleen cells used for adoptive
transfer were obtained from AG129 mice 6–11 weeks after infection
with 105 PFU of either DENV1 98J or DENV2 PL046, or from age-
matched controls. To prepare polyclonal serum, blood was collected
via cardiac puncture, allowed to clot, and then serum was removed
and pooled. To prepare immune cells for adoptive transfer, spleens
were collected from mice and pressed through a 100 μM cell ﬁlter,
red blood cells were lysed, and cells were resuspended in
“complete RPMI” (RPMI [Invitrogen] with 10% FBS, 10 mM HEPES,
1× P/S) at a density of either 6×107 cells/mL or 1.5×108 cells/mL
(1–3×107 cells/mouse).
Preparation of spleen cells for carboxyﬂuorescein diacetate
succinimidyl ester (CFSE) labeling and detection by ﬂow cytometry
Spleens were collected from mice and prepared as above, and cells
were resuspended in PBS with 0.5% bovine serum albumin (BSA,
Fisher Scientiﬁc) and 5% FBS. Cells were adjusted to a density of 108
cells/mL, added to an equal volume of 20 μM CFSE (AnaSpec), and
incubated for 10 min at room temperature. Staining was quenched by
addition of 10X volume of ice-cold complete RPMI, followed by two
more washes in the samemedium. Cells were resuspended at 1.5×108
cells/mL in Hank's Balanced Salt Solution (HBSS; Invitrogen) for
intravenous (iv) injection into mice (3×107 cells/mouse). After 36 h,
spleens frommice injected with CFSE-labeled cells were collected and
resuspended in PBS–0.5% BSA–0.02% sodium azide (Sigma), ﬁxed in 4%
paraformaldehyde, and stored at 4 °C until analysis on a Coulter EPICS
XL (Beckman Coulter). Results were analyzed using FlowJo software,
version 5.7.2 (TreeStar).
ELISA detection of IFN-γ in cell culture supernatants
Spleens were collected from mice and prepared as above, and cells
were resuspended in complete RPMI. Antigen stimulation was
performed with 20 μg/mL of DENV2 PL046-infected C6/36 cell lysate
(cellular antigen) prepared at day 7 after infection or control cellular
lysate from uninfected C6/36 cells, both diluted in sterile PBS. Controls
included PBS alone and 5 μg/mL of Concanavalin A (Sigma) in PBS.
Cells were processed according to manufacturer's instructions for
mouse IFN-γ ELISA (Mabtech). Supernatants for detection of secreted
IFN-γwere collected from control wells after 3 days and from antigen-
stimulated wells after 7 days. Optical density was read at 405 nm on
an ELX808 Ultra Microplate Reader (Bio-tek Instruments), and results
are shown from an average of triplicate wells.
Statistical analysis
Statistical analysis of the difference between means was per-
formed with STATA 7.0 (STATA Corporation) using the Wilcoxon Rank
302 J.L. Kyle et al. / Virology 380 (2008) 296–303Sum test. Non-parametric statistics were used for analysis, since they
make no assumptions about the underlying populations analyzed.
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